Composition comprising at least two influenza A virus-neutralizing-binding molecules

A composition comprising at least two influenza A virus-neutralizing binding molecules that bind to an epitope in a stem region of influenza A virus hemagglutinin (HA) protein, the composition comprising:

• i) a first binding molecule capable of neutralizing at least one influenza A virus subtype selected from the group consisting of H1, H2, H5 and H9;
• wherein the first binding molecule comprises any one polypeptide selected from the group consisting of:
• i) a polypeptide comprising a light-chain variable region comprising, as determined according to the Kabat method, a CDR1 region of SEQ ID NO:
• 1, a CDR1 region of SEQ ID NO:
• 2 and a CDR3 region of SEQ ID NO:
• 3, and a heavy-chain variable region comprising, as according to the Kabat method, a CDR1 region of SEQ ID NO:
• 4, a CDR2 region of SEQ ID NO:
• 5 and a CDR3 region of SEQ ID NO:
• 6;
• ii) a polypeptide comprising a light-chain variable region comprising, as determined according to the Kabat method, a CDR1 region of SEQ ID NO:
• 7, a CDR2 region of SEQ ID NO:
• 8 and a CDR3 region of SEQ ID NO:
• 9, and a heavy-chain variable region comprising, as according to the Kabat method, a CDR1 region of SEQ ID NO:
• 10, a CDR2 region of SEQ ID NO:
• 11 and a CDR3 region of SEQ ID NO:
• 12;
• and
• iii) a polypeptide comprising a light-chain variable region comprising, as determined according to the Kabat method, a CDR1 region of SEQ ID NO:
• 13, a CDR2 region of SEQ NO:
• 14 and a CDR3 region of SEQ ID NO:
• 15, and a heavy-chain variable region comprising, as according to the Kabat method, a CDR1 region of SEQ ID NO:
• 16, a CDR2 region of SEQ ID NO:
• 17 and a CDR3 region of SEQ ID NO:
• 18;
• and
• ii) a second binding molecule capable of neutralizing at least one influenza A virus subtype selected from the group consisting of H1, H3, H5, H7 and H9,
• wherein the second binding molecule comprises any one polypeptide selected from the group consisting of:
• i) a polypeptide comprising a light-chain variable region comprising, as determined according to the Kabat method, a CDR1 region of SEQ ID NO:
• 19, a CDR2 region of SEQ ID NO:
• 20 and a CDR3 region of SEQ ID NO:
• 21, and a heavy-chain variable region comprising, as according to the Kabat method, a CDR1 region of SEQ ID NO:
• 22, a CDR2 region of SEQ NO:
• 23 and a CDR3 region of SEQ ID NO:
• 24;
• ii) a polypeptide comprising a light-chain variable region comprising, as determined according to the Kabat method, a CDR1 region of SEQ ID NO:
• 25, a CDR2 region of SEQ ID NO:
• 26 and a CDR3 region of SEQ ID NO:
• 27, and a heavy-chain variable region comprising, as according to the Kabat method, a CDR1 region of SEQ ID NO:
• 28, a CDR2 region of SEQ ID NO:
• 29 and a CDR3 region of SEQ ID NO:
• 30;
• iii) a polypeptide comprising a light-chain variable region comprising, as determined according to the Kabat method, a CDR1 region of SEQ ID NO:
• 31, a CDR2 region of SEQ ID NO:
• 32 and a CDR3 region of SEQ ID NO:
• 33, and a heavy-chain variable region comprising, as according to the Kabat method, a CDR1 region of SEQ ID NO:
• 34, a CDR2 region of SEQ ID NO:
• 35 and a CDR3 region of SEQ ID NO:
• 36;
• and
• iv) a polypeptide comprising a light-chain variable region comprising, as determined according to the Kabat method, a CDR1 region of SEQ ID NO:
• 37, a CDR2 region of SEQ ID NO:
• 38 and a CDR3 region of SEQ ID NO:
• 39, and a heavy-chain variable region comprising, as according to the Kabat method, a CDR1 region of SEQ ID NO:
• 40, a CDR2 region of SEQ ID NO:
• 41 and a CDR3 region of SEQ ID NO:
• 42;
• and
• wherein the first and second binding molecules are produced by a CHO cell culture.